Brokerages Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) PT at $10.88

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) has been assigned an average rating of “Hold” from the ten analysts that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $10.88.

TEVA has been the topic of a number of research analyst reports. Jefferies Financial Group cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and upped their price target for the company from $10.00 to $12.00 in a research report on Thursday, January 19th. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Thursday, February 9th. JPMorgan Chase & Co. downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and cut their price objective for the stock from $11.00 to $10.00 in a report on Monday, November 14th. Finally, Piper Sandler cut their price target on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, November 23rd.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 63,383 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total value of $626,857.87. Following the completion of the sale, the vice president now owns 2,974 shares in the company, valued at approximately $29,412.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Teva Pharmaceutical Industries news, EVP Sven Dethlefs sold 19,355 shares of the business’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $9.93, for a total transaction of $192,195.15. Following the completion of the transaction, the executive vice president now owns 223,447 shares in the company, valued at approximately $2,218,828.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP David Matthew Stark sold 63,383 shares of the business’s stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total value of $626,857.87. Following the transaction, the vice president now owns 2,974 shares of the company’s stock, valued at approximately $29,412.86. The disclosure for this sale can be found here. Insiders sold a total of 158,884 shares of company stock valued at $1,572,797 over the last three months. 0.82% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently modified their holdings of the company. Credit Suisse AG lifted its holdings in Teva Pharmaceutical Industries by 7.6% during the third quarter. Credit Suisse AG now owns 7,418,922 shares of the company’s stock worth $59,871,000 after acquiring an additional 524,548 shares in the last quarter. AIA Group Ltd increased its holdings in Teva Pharmaceutical Industries by 27.4% in the second quarter. AIA Group Ltd now owns 21,946 shares of the company’s stock valued at $165,000 after purchasing an additional 4,725 shares during the period. Truist Financial Corp boosted its position in Teva Pharmaceutical Industries by 19.0% during the third quarter. Truist Financial Corp now owns 159,361 shares of the company’s stock valued at $1,286,000 after acquiring an additional 25,472 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Teva Pharmaceutical Industries by 705.1% during the 3rd quarter. Two Sigma Investments LP now owns 5,283,501 shares of the company’s stock worth $42,638,000 after purchasing an additional 4,627,252 shares in the last quarter. Finally, Prospera Financial Services Inc lifted its position in Teva Pharmaceutical Industries by 78.6% in the 3rd quarter. Prospera Financial Services Inc now owns 61,810 shares of the company’s stock valued at $499,000 after acquiring an additional 27,197 shares in the last quarter. Institutional investors and hedge funds own 50.39% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $9.12 on Friday. The business has a 50 day moving average price of $10.26 and a 200 day moving average price of $9.27. The company has a quick ratio of 0.72, a current ratio of 1.05 and a debt-to-equity ratio of 2.20. Teva Pharmaceutical Industries has a twelve month low of $6.78 and a twelve month high of $11.44. The company has a market cap of $10.13 billion, a price-to-earnings ratio of -4.30, a PEG ratio of 2.70 and a beta of 1.22.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last announced its quarterly earnings results on Wednesday, February 8th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.04. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.90 billion. Teva Pharmaceutical Industries had a positive return on equity of 28.06% and a negative net margin of 15.76%. Research analysts predict that Teva Pharmaceutical Industries will post 2.31 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.